PH12021550114A1 - T cell-antigen coupler with various construct optimizations - Google Patents
T cell-antigen coupler with various construct optimizationsInfo
- Publication number
- PH12021550114A1 PH12021550114A1 PH12021550114A PH12021550114A PH12021550114A1 PH 12021550114 A1 PH12021550114 A1 PH 12021550114A1 PH 12021550114 A PH12021550114 A PH 12021550114A PH 12021550114 A PH12021550114 A PH 12021550114A PH 12021550114 A1 PH12021550114 A1 PH 12021550114A1
- Authority
- PH
- Philippines
- Prior art keywords
- optimizations
- cell
- different
- ucht1
- antigen coupler
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 238000005457 optimization Methods 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 3
- 229940127174 UCHT1 Drugs 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 108091008874 T cell receptors Proteins 0.000 abstract 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862699173P | 2018-07-17 | 2018-07-17 | |
US201862703037P | 2018-07-25 | 2018-07-25 | |
US201862773120P | 2018-11-29 | 2018-11-29 | |
US201962826853P | 2019-03-29 | 2019-03-29 | |
US201962828879P | 2019-04-03 | 2019-04-03 | |
US201962839235P | 2019-04-26 | 2019-04-26 | |
US16/442,274 US10640562B2 (en) | 2018-07-17 | 2019-06-14 | T cell-antigen coupler with various construct optimizations |
US201962874426P | 2019-07-15 | 2019-07-15 | |
PCT/US2019/042297 WO2020018727A1 (en) | 2018-07-17 | 2019-07-17 | T cell-antigen coupler with various construct optimizations |
Publications (1)
Publication Number | Publication Date |
---|---|
PH12021550114A1 true PH12021550114A1 (en) | 2021-10-04 |
Family
ID=69163917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH12021550114A PH12021550114A1 (en) | 2018-07-17 | 2021-01-15 | T cell-antigen coupler with various construct optimizations |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3823984A4 (en) |
JP (1) | JP7404279B2 (en) |
KR (1) | KR20210021593A (en) |
CN (1) | CN112689642A (en) |
AU (1) | AU2019307905A1 (en) |
BR (1) | BR112021000735A2 (en) |
CA (1) | CA3104887A1 (en) |
IL (1) | IL280049A (en) |
MX (1) | MX2021000541A (en) |
PH (1) | PH12021550114A1 (en) |
SG (1) | SG11202100307WA (en) |
WO (1) | WO2020018727A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10435453B2 (en) | 2014-02-07 | 2019-10-08 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
EP3694997A4 (en) | 2017-10-12 | 2021-06-30 | Mcmaster University | T cell-antigen coupler with y182t mutation and methods and uses thereof |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
US10640562B2 (en) | 2018-07-17 | 2020-05-05 | Mcmaster University | T cell-antigen coupler with various construct optimizations |
EP4326889A2 (en) | 2021-04-21 | 2024-02-28 | Conagen Inc. | Biosynthetic production of delta-lactones using cytochrome p450 hydroxylase enzymes or mutants thereof |
WO2022256449A1 (en) | 2021-06-01 | 2022-12-08 | Triumvira Immunologics Usa, Inc. | Claudin 18.2 t cell-antigen couplers and uses thereof |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2794658T (en) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecific antibody molecule |
SG11201408787PA (en) * | 2012-07-13 | 2015-01-29 | Univ Pennsylvania | Enhancing activity of car t cells by co-introducing a bispecific antibody |
US10435453B2 (en) | 2014-02-07 | 2019-10-08 | Mcmaster University | Trifunctional T cell-antigen coupler and methods and uses thereof |
MX2017012939A (en) * | 2015-04-08 | 2018-05-22 | Novartis Ag | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell. |
WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
EP3472318B1 (en) * | 2016-07-08 | 2023-09-06 | Exuma Biotech Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
WO2018027155A1 (en) | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
CN108250302A (en) * | 2016-12-29 | 2018-07-06 | 天津天锐生物科技有限公司 | A kind of multifunctional protein |
-
2019
- 2019-07-17 CA CA3104887A patent/CA3104887A1/en active Pending
- 2019-07-17 SG SG11202100307WA patent/SG11202100307WA/en unknown
- 2019-07-17 CN CN201980047935.6A patent/CN112689642A/en active Pending
- 2019-07-17 EP EP19838648.4A patent/EP3823984A4/en active Pending
- 2019-07-17 BR BR112021000735-0A patent/BR112021000735A2/en unknown
- 2019-07-17 MX MX2021000541A patent/MX2021000541A/en unknown
- 2019-07-17 KR KR1020217004572A patent/KR20210021593A/en unknown
- 2019-07-17 AU AU2019307905A patent/AU2019307905A1/en active Pending
- 2019-07-17 JP JP2020571816A patent/JP7404279B2/en active Active
- 2019-07-17 WO PCT/US2019/042297 patent/WO2020018727A1/en unknown
-
2021
- 2021-01-10 IL IL280049A patent/IL280049A/en unknown
- 2021-01-15 PH PH12021550114A patent/PH12021550114A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2021000541A (en) | 2021-08-16 |
EP3823984A4 (en) | 2022-04-06 |
WO2020018727A1 (en) | 2020-01-23 |
CN112689642A (en) | 2021-04-20 |
KR20210021593A (en) | 2021-02-26 |
BR112021000735A2 (en) | 2021-07-13 |
EP3823984A1 (en) | 2021-05-26 |
AU2019307905A1 (en) | 2021-03-04 |
JP2021530971A (en) | 2021-11-18 |
JP7404279B2 (en) | 2023-12-25 |
CA3104887A1 (en) | 2020-01-23 |
SG11202100307WA (en) | 2021-02-25 |
IL280049A (en) | 2021-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550114A1 (en) | T cell-antigen coupler with various construct optimizations | |
EP4249068A3 (en) | Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies | |
IL265541B1 (en) | Bispecific antibodies and compositions comprising thereof for treating cancer | |
MX2019003350A (en) | Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases. | |
JP2017504578A5 (en) | ||
MX2022001273A (en) | Heterotandem bicyclic peptide complex. | |
JP2015502373A5 (en) | ||
MX2016015389A (en) | Antibodies binding to human and cynomolgus cd3 epsilon. | |
SG195077A1 (en) | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes | |
JP2017504577A5 (en) | ||
WO2019005640A3 (en) | Multi-specific antibodies and methods of making and using thereof | |
MX2020002880A (en) | Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1). | |
RU2013157040A (en) | POLYVALENT ANTIGEN-BINDING FV-MOLECULE | |
JOP20200234A1 (en) | Modified a1-a2 domains of non-natural nkg2d ligands that bind non-natural nkg2d receptors | |
JP2024023228A5 (en) | ||
EA201691782A1 (en) | ANTIBODIES SPECIFIC TO THE RECEPTOR OF INSULIN-LIKE GROWTH FACTOR 1, AND THEIR APPLICATION | |
RU2018137419A (en) | BINDING TO CD38 AND PD-L1 MOLECULES | |
EA201691779A1 (en) | ANTIBODIES SPECIFIC TO THE RECEPTOR OF INSULIN-LIKE GROWTH FACTOR 1, AND THEIR APPLICATION | |
MX2023010499A (en) | Heterodimeric antibodies that bind cd3 and cldn6. | |
PH12020551661A1 (en) | Anti-pd-l1 antibody and use thereof | |
WO2019195623A3 (en) | Heterodimeric antibodies that bind fibroblast activation protein | |
MX2023009022A (en) | Multispecific antibodies having specificity for ror1 and cd3. | |
MX2021009275A (en) | Cd3-specific binding molecules. | |
ZA202107047B (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof |